Menu
Back to Journals » International Journal of Nanomedicine » Volume 19
Comparative Colloidal Stability of Commercial Amphotericin B Nanoformulations Using Dynamic and Static Multiple Light Scattering Techniques [Corrigendum]
Ye J, Li R, Cheng J, et al. Int J Nanomedicine. 2022;17:6047–6064.
The authors have advised that there is an error in Figure 9 on page 6060 of the published paper. Due to an error that occurred inadvertently at the time of figure assembly, figure part D is incorrect. Although it does not affect the conclusion that AmB nanoformulations can significantly promote macrophage proliferation when incubated with high concentrations, it is an obvious mistake. The correct Figure 9 is as follows.
 |
Figure 9 Continued. |
 |
Figure 9 In vitro cytotoxicity of AmB injection, AmB-CSC, and AmB-Lipo in murine RAW264.7 macrophages. The murine RAW264.7 macrophages were treated with AmB injection (A), AmB-CSC (C), and AmB-Lipo (E) at AmB concentrations of 0.1–50 µg/mL for 24 h and the cell viability was determined using CCK-8 kits. Each value represents the mean ± SEM (n = 6). ***p < 0.001 compared with the control (Ctrl) group. The cell morphology of RAW264.7 macrophages after incubation with AmB injection (B), AmB-CSC (D), and AmB-Lipo (F) was observed by Cell Imaging Multimode Reader (Cytation 5, BioTek). Abbreviations: AmB, amphotericin B; AmB-CSC, AmB cholesteryl sulfate complex; AmB-Lipo, AmB liposome; SEM, standard error of the mean. |
The authors apologise for this error.
© 2024 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution
- Non Commercial (unported, 3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.